American Century Companies’s Black Diamond Therapeutics BDTX Stock Holding History
Bought
Maintained
Sold
Other funds holding BDTX
NMC
DCM
American Century Companies's BDTX Position: Q2 2026 in Review
American Century Companies reduced its Black Diamond Therapeutics (BDTX) stake by 11% in Q2 2026, selling an estimated $23.8K and leaving 81,311 shares worth $150K. The position accounts for ﹤0.01% of the portfolio, ranked #2807.
American Century Companies first reported a position in BDTX in Q2 2025 and has held it in 5 quarters since. The position peaked at $350K in Q3 2025. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.
- American Century Companies held 81,311 shares of Black Diamond Therapeutics worth $150K as of Q2 2026.
- American Century Companies sold 9,735 Black Diamond Therapeutics shares in Q2 2026, an estimated $23.8K.
- Black Diamond Therapeutics made up ﹤0.01% of American Century Companies's portfolio in Q2 2026, its #2807 holding.
- American Century Companies first reported a position in Black Diamond Therapeutics in Q2 2025 and has held it in 5 quarters since.
- American Century Companies's Black Diamond Therapeutics position peaked at $350K in Q3 2025.
- 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.
Based on American Century Companies's 13F filing for Q2 2026, filed 12 Aug 2026.